Status:
UNKNOWN
Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells
Lead Sponsor:
Hadassah Medical Organization
Conditions:
BRCA1 Gene Mutation
BRCA2 Gene Mutation
Eligibility:
FEMALE
25-50 years
Brief Summary
Susceptibility to breast cancer is related to the combination of genetic, hormonal and multiple other environmental risk factors, such as mutations in the BRCA gene and excess exposure to exogenous es...
Detailed Description
To study the different cell lineages, we plan to isolate and propagate luminal progenitors from a normal human breast tissue. To this end, 10 human breast tissue samples will be obtained from risk-red...
Eligibility Criteria
Inclusion
- healthy
- premenopausal
- women
- BRCA1 mutations
- BRCA2 mutations
Exclusion
- women with breast or ovarian cancer
Key Trial Info
Start Date :
September 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01907438
Start Date
September 1 2013
End Date
September 1 2015
Last Update
July 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah medical center
Jerusalem, Israel